474 related articles for article (PubMed ID: 16622600)
21. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.
De Buck SS; Sinha VK; Fenu LA; Nijsen MJ; Mackie CE; Gilissen RA
Drug Metab Dispos; 2007 Oct; 35(10):1766-80. PubMed ID: 17620347
[TBL] [Abstract][Full Text] [Related]
22. Beta-peptidic peptidomimetics.
Seebach D; Gardiner J
Acc Chem Res; 2008 Oct; 41(10):1366-75. PubMed ID: 18578513
[TBL] [Abstract][Full Text] [Related]
23. The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice.
Lee DW; Leinung MC; Grasso P
Regul Pept; 2008 Oct; 150(1-3):62-5. PubMed ID: 18455249
[TBL] [Abstract][Full Text] [Related]
24. Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase.
Fontana A; Spolaore B; Mero A; Veronese FM
Adv Drug Deliv Rev; 2008 Jan; 60(1):13-28. PubMed ID: 17916398
[TBL] [Abstract][Full Text] [Related]
25. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
[TBL] [Abstract][Full Text] [Related]
26. Peptide-based inhibitors of amyloid assembly.
Sciarretta KL; Gordon DJ; Meredith SC
Methods Enzymol; 2006; 413():273-312. PubMed ID: 17046402
[TBL] [Abstract][Full Text] [Related]
27. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
28. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
Youn YS; Lee KC
Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
[TBL] [Abstract][Full Text] [Related]
29. The proteolytic stability and cytotoxicity studies of L-aspartic acid and L-diaminopropionic acid derived beta-peptides and a mixed alpha/beta-peptide.
Ahmed S; Kaur K
Chem Biol Drug Des; 2009 May; 73(5):545-52. PubMed ID: 19317848
[TBL] [Abstract][Full Text] [Related]
30. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
Fan Q; Leuther KK; Holmes CP; Fong KL; Zhang J; Velkovska S; Chen MJ; Mortensen RB; Leu K; Green JM; Schatz PJ; Woodburn KW
Exp Hematol; 2006 Oct; 34(10):1303-11. PubMed ID: 16982323
[TBL] [Abstract][Full Text] [Related]
31. Development of poly(ethylene glycol) conjugated lactoferrin for oral administration.
Nojima Y; Suzuki Y; Iguchi K; Shiga T; Iwata A; Fujimoto T; Yoshida K; Shimizu H; Takeuchi T; Sato A
Bioconjug Chem; 2008 Nov; 19(11):2253-9. PubMed ID: 18834167
[TBL] [Abstract][Full Text] [Related]
32. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
33. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
35. Studies of the inhibition of serum pseudocholinesterase activity in vitro by commonly used drugs.
Bailey DN; Briggs JR
Am J Clin Pathol; 2005 Aug; 124(2):226-8. PubMed ID: 16040293
[TBL] [Abstract][Full Text] [Related]
36. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy.
Lee TY; Tjin Tham Sjin RM; Movahedi S; Ahmed B; Pravda EA; Lo KM; Gillies SD; Folkman J; Javaherian K
Clin Cancer Res; 2008 Mar; 14(5):1487-93. PubMed ID: 18316573
[TBL] [Abstract][Full Text] [Related]
37. Hyaluronan-tethered opioid depots: synthetic strategies and release kinetics in vitro and in vivo.
Gianolio DA; Philbrook M; Avila LZ; Young LE; Plate L; Santos MR; Bernasconi R; Liu H; Ahn S; Sun W; Jarrett PK; Miller RJ
Bioconjug Chem; 2008 Sep; 19(9):1767-74. PubMed ID: 18717537
[TBL] [Abstract][Full Text] [Related]
38. Clearance of von Willebrand factor.
Denis CV; Christophe OD; Oortwijn BD; Lenting PJ
Thromb Haemost; 2008 Feb; 99(2):271-8. PubMed ID: 18278174
[TBL] [Abstract][Full Text] [Related]
39. Lamellipodin proline rich peptides associated with native plasma butyrylcholinesterase tetramers.
Li H; Schopfer LM; Masson P; Lockridge O
Biochem J; 2008 Apr; 411(2):425-32. PubMed ID: 18076380
[TBL] [Abstract][Full Text] [Related]
40. The dynamics of protein decomposition in lakes of different trophic status--reflections on the assessment of the real proteolytic activity in situ.
Siuda W; Kiersztyn B; Chróst RJ
J Microbiol Biotechnol; 2007 Jun; 17(6):897-904. PubMed ID: 18050906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
